Igc pharma expands ai platform with advanced diagnostic model for alzheimer's and dementia detection

Potomac, md / access newswire / march 4, 2025 / igc pharma, inc. ("igc" or the "company") (nyse american:igc) today announced an advancement in its artificial intelligence ("ai") platform with the development of a new ai-driven model designed to improve the diagnosis of alzheimer's disease (ad) and other causes of dementia. with alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular disease, lewy body disease, and frontotemporal degeneration, accurate diagnosis is critical to ensuring the right treatment strategy.
IGC Ratings Summary
IGC Quant Ranking